A detailed history of Rathbones Group PLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Rathbones Group PLC holds 1,454 shares of VRTX stock, worth $594,337. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,454
Previous 1,099 32.3%
Holding current value
$594,337
Previous $515,000 31.26%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$460.0 - $505.78 $163,300 - $179,551
355 Added 32.3%
1,454 $676,000
Q2 2024

Aug 09, 2024

SELL
$392.81 - $485.53 $223,901 - $276,752
-570 Reduced 34.15%
1,099 $515,000
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $72,976 - $79,848
179 Added 12.01%
1,669 $697,000
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $77,861 - $93,224
227 Added 17.97%
1,490 $606,000
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $427,121 - $457,786
1,263 New
1,263 $439,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Rathbones Group PLC Portfolio

Follow Rathbones Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rathbones Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Rathbones Group PLC with notifications on news.